All News
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
Day 1 Report from ACR21
The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
Read Article
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics
⭐️HR 1.39
⭐️retrospective cohort study w/ >1300 cases
Abs#1355
#ACR21
#ACRBest
@RheumNow
https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Robert B Chao, MD doctorRBC ( View Tweet)
In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated
patients, irrespective of controlled or non-controlled inflammation, as
measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS
Dr. Antoni Chan synovialjoints ( View Tweet)
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway RichardPAConway ( View Tweet)
Study on enthesitis response to biologic Rx
⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab
⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab
🔰Superiority of TNFi versus secukinumab in regards to active enthesitis
Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
swethaann23 swethaann23 ( View Tweet)
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
Richard Conway RichardPAConway ( View Tweet)
Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
Richard Conway RichardPAConway ( View Tweet)
A meta-analysis of 5 cohort studies showed that PsA is significantly associated with vertebral fractures pooled OR 2.09 (95% CI, 1.11 – 3.96; I2 70%). The review was not suggestive of publication bias
@RheumNow #ACR21 Abst#1304 https://t.co/rjC776FXUA https://t.co/QvMWxN6ZZ7
Dr. Antoni Chan synovialjoints ( View Tweet)
Meta-analysis shows increased risk of vertebral fracture in PsA, OR 2.09. Abstr#1304 #ACR21 @RheumNow https://t.co/kTrR7I3HA0
Richard Conway RichardPAConway ( View Tweet)
Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD
MDA achievers were:
➡️Younger
➡️🔽 Disease duration;
➡️ Male
➡️Non-obese
➡️bDMARD-naïve at baseline
➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo
Abst# 1344 #ACR21 @Rheumnow
swethaann23 swethaann23 ( View Tweet)
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway RichardPAConway ( View Tweet)
AS and PsA: Mortality vs Gen Pop (meta-analysis)
AS:
👉⬆️All-cause
👉⬆️CVD
PsA:
👉All-cause not higher
👉⬆️CVD, Respiratory, and Infectious etiologies
Important to consider CVD and other comorbidities.
https://t.co/9K4qNpYvMb
#ACR21 Abst#0569 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
"Healthier moms lead to healthier babies. This is how I frame the discussion regarding medications and PsA in my practice (with regard to reproductive health)." Dr. Talabi #ACR21 @RheumNow #RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
PsA impacts many aspects of life. PRO such as VAS pain
and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by
patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ
Dr. Antoni Chan synovialjoints ( View Tweet)
With Deucravacitinib, a TYK2 inhibitor vs placebo, PsAID-12 and PsAID-9 scores were significantly improved
versus baseline at Week 16
and other PROs showing a clear improvement in PsA-related impact @RheumNow #ACR21 Abst#0750 https://t.co/JbeSE2dO94 https://t.co/pH79dXCYSs
Dr. Antoni Chan synovialjoints ( View Tweet)
🌞😎🍣 Vitamin D and Omega-3 FA ⬇️ Risk of developing autoimmune disease
1st prospective, randomized, double blind, placebo controlled trial
Vit D 2000IU and/or Omega 3-FA 1000mg ⬇️autoimmune disease by 25-30%
#ACR21 #ACRBest @RheumNow
Abs#957
https://t.co/7dODuplg7e https://t.co/GUKhYXbSXU
Robert B Chao, MD doctorRBC ( View Tweet)
Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using mass spectrometry, found differences in both synovial bx and fluid. Potentially useful lipid markers, more studies to follow.
#ACR21 #ACRBest Abst#0946 @RheumNow https://t.co/KmWCPKijSx
Pedro Castillo _Castillo_Pedro ( View Tweet)
Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordant for psoriatic disease. (red = Psoriatic). Gut ruminococcus bromii virtually absent in psoriatic pts. Eager to see further studies!
#ACR21 Abst#0944 @RheumNow https://t.co/zrZPBAjh5p
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid.
Sphingomyelins & phosphatidyl-cholines/ethanolamines had the greatest separation power to classify RA + PsA samples. These lipid markers may have clinical utility if validated.
#ACR21 @Rheumnow https://t.co/ktKRypTtlE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
